The launch marks a pivotal step in the clinical development of engineered solutions aimed at addressing aging biology, with a focus on tissue repair, age-related diseases, and longevity.

Unlike therapies that target specific diseases, 600and1's approach targets the systemic biology of aging by focusing on aging-modulating genes and pathways.

Biotech startup 600and1, recognized as a unicorn in the longevity sector, has initiated a comprehensive effort to decode and bioengineer the biology of aging.

This initiative involves mapping cellular and molecular processes that drive aging through genomics, cell biology, AI, and bioengineering across various tissues and cell types.

Funding for this effort supports infrastructure, talent acquisition, and accelerated product development, highlighting increasing investor interest in longevity.

The company plans to develop engineered therapies, including cellular, genetic, and molecular treatments, to restore youthful function and combat age-related diseases.